Daledalin

Daledalin' (developmental code name UK-3557-15) is a pharmacological compound that was explored as an antidepressant during the early 1970s. Despite the promise shown in initial synthesis and clinical trials for treating depression, Daledalin was ultimately not brought to market. Classified as a norepinephrine reuptake inhibitor, Daledalin is noted for its selective mechanism of action, specifically inhibiting the reuptake of norepinephrine without significantly affecting the reuptake of other neurotransmitters such as serotonin and dopamine. Additionally, it lacks antihistamine and anticholinergic properties, distinguishing it from many other antidepressants with broader receptor activity profiles.

Pronunciation

Day-leh-dah-lin

Pharmacodynamics

Daledalin's mechanism as a selective norepinephrine reuptake inhibitor highlights its potential role in modulating mood and affective states. By specifically targeting norepinephrine reuptake, Daledalin aimed to increase the availability of this neurotransmitter in the synaptic cleft, potentially alleviating symptoms of depression. The selectivity of Daledalin could have offered advantages in terms of side effect profiles compared to less selective antidepressants.

Clinical Development and Discontinuation

The development of Daledalin in the 1970s included synthesis and clinical trials aimed at evaluating its efficacy and safety for depression treatment. Despite the initial research, the decision not to market Daledalin may have been influenced by a variety of factors, including efficacy results, competition from other antidepressants, or potential safety concerns. The discontinuation of its development underscores the challenges in drug development, particularly in the psychiatric medication domain.

Related Terms

• Antidepressant
• Norepinephrine
• Clinical Depression
• Pharmacology
• Selective Norepinephrine Reuptake Inhibitors

See Also

• Amedalin
• Drug Development Process
• Mood Disorders
• Neurotransmitters